Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation , today announced data from a study comparing melphalan, prednisone and REVLIMID with high-dose chemotherapy and tandem autologous stem cell transplant , as well as evaluating the effect of lenalidomide maintenance in patients with newly-diagnosed multiple myeloma were ... (more)
http://news.investors.com/newsfeed-business-wire/060313-141486937-study-evaluating-revlimid-combination-compared-to-autologous-stem-cell-transplant-with-or-without-revlimid-maintenance-in-newly-diagnosed-multiple-myeloma-presented-at-asco.aspx
http://news.investors.com/newsfeed-business-wire/060313-141486937-study-evaluating-revlimid-combination-compared-to-autologous-stem-cell-transplant-with-or-without-revlimid-maintenance-in-newly-diagnosed-multiple-myeloma-presented-at-asco.aspx
No comments:
Post a Comment